INTERNATIONAL MEETINGS:


2. X International Congress of Allergology: Jerusalem, Israel, November 4-11, 1979, "Allergic and Other Adverse Reactions Caused by the Imported Fire Ant".

3. XLIV Congreso Medico Nacional II Congreso Centroamericano de Farmacologia y Terapeutica, San Jose, Costa Rica, December 4-7, 1979,
   1) "Advances in the Treatment of Asthma",
   2) "Immunopathological Reactions in Clinical Medicine",
   3) "Participant in round table on Environmentally Induced Lung Disease".


5. Interasma Mexico '84, Mexico City, Mexico, October 21-25, 1984, "Effects of the Toxin of Red Tide, Ptychodiscus brevis (PBTX), on Canine Tracheal Smooth Muscle (CTSM): A Possible New Asthma Triggering Mechanism."


10. XII International Congress of Allergology and Clinical Immunology, Washington D.C., October 20-25, 1985. Meet the Professor Breakfast, "Food Additives".


13. XII World Congress of Asthmaology - InterAsma '87, Barcelona, Spain, October 25-29, 1987, "Red Tide Toxin Induced Bronchial Smooth Muscle Contraction”.

14. Shering Compania Limitada, Santiago, Chile, April 29, 1988, "Allergy and Loratadine”.


16. Canadian Society of Allergy and Clinical Immunology, The Royal College of Physicians and Surgeons of Canada, 57th Annual Meeting, Ottawa, Canada, September 23-26, 1988, "Adverse Effects of Immunotherapy”.

17. Visiting Professor, Damas Hospital Residency Teaching Program Annual Meeting, Ponce, Puerto Rico, October 27-28, 1988, "Evaluation of the Immunodeficient Patient”, "Allergic Mechanisms (Type I-IV) and Clinical Medicine" and "Urticaria - Etiology and Treatment”.


23. Fifth International Conference on Immunopharmacology, Tampa, Florida, May 30, 1991, "The Elution Profile of the A549 Beta Adrenergic (BAR) Regulating Activity of Lymphocyte Conditioned Medium (LCM) of IM9 Cells Developed by DEAE Ion Exchange HLPC," "Adrenergic and Histamine Receptor Concentrations in Bone Marrow Cells (BMC)," "The Nature of the Adrenergically Active Constituents of Lymphocyte Conditioned Medium (LCM) of IM9 Cells," "Sensitization of Bone Marrow Hemopoietic Progenitor Cells (BMC) to the Interleukin-3 (IL-3) and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Induced De Novo Synthesis of Histidine Decarboxylase HDC) Through the Activation of Beta-Adrenoceptors (BAR)."


25. XIV International Congress of Allergology and Clinical Immunology, Kyoto, Japan, October 13-18, 1991, "Mite-Specific IgE In Pediatric Asthma". (Did not appear, but co-authored).

26. Invited Guest, Simposio Internacional De Alergia E Inmunologia, Cordoba, Argentina, November 6-8, 1991, "Insect Allergy" and "Allergen Immuno-therapy, Past, Present and Future".

27. Kay AB, Bonini S, Lockey RF, Moderators, Joint Session European Association of Allergology and Clinical Immunology and American Academy of Allergy and Immunology, European Congress of Allergology and Clinical Immunology, Paris, France, May 13, 1992.

28. Lockey RF, Moderator, Joint Symposium European Association of Allergology and Clinical Immunology and American Academy of Allergy and Immunology, Rotterdam, The Netherlands, September 12-15, 1993, "Respiratory Immunotoxicology of Small Molecular Weight Compounds".


30. Lockey RF, Plenary Speaker, Latin American Society of Allergy and Immunology, Margarita, Venezuela, September 29 - October 2, 1993, "Insect Allergy" and "Systemic Reactions from Skin Testing and Immunotherapy".

31. Advances in Allergy and Asthma: The XV International Congress of Allergology and Clinical Immunology and the Annual Meeting of the European Academy of Allergology and Clinical Immunology, Helsinki, Finland; St. Petersburg, Russia, July 2-3 and July 5-6, 1994, "Allergen Immunotherapy".

33. II International Workshop of Allergy and Immunology, Belo Horizonte, Brazil, August 17 - 19, 1995, "Rhinitis - How do I treat it?", "What is new in Sinusitis", "Asthma or Bronchitis: What is new?" and "Immunotherapy: Risks and Benefits".


40. XV Chilean Congress of Allergy and Immunology, sponsored by the Chilean Society of Allergy and Clinical Immunology, Santiago, Chile, August 29, 1997, Round Table: "Advances in the Pharmacological Treatment of Allergic Diseases"; Plenary Conference: "Diagnosis and Treatment of Chronic Sinusitis"; Round Table: "Immunotherapy in Allergic Diseases".

41. ICACI XVI (XVI International Congress of Allergology and Clinical Immunology). Main symposium: 8. Immunotherapy - Advances and Follow-Up: (Venom Immunotherapy), Cancun, Mexico, October 23, 1997, "Clinical presentation, Diagnosis and Treatment of Insect Hypersensitivity".

43. International Jubilee Symposium - 30 years with IgE, City Hall, Stockholm, Sweden (site of Nobel Prize Awards), September 1-2, 1998, "Toast on behalf of the American Academy of Allergy Asthma and Immunology for the discovery of IgE, and on behalf of Dr. Gunnar Johanssen”.

44. The XVI World Congress of Asthma, Buenos Aires, Argentina, October 17 - 20, 1999, “Immunotherapy in Asthma: Yes or No”.


46. VI International Congress on Immunorehabilitation – Advances in Immunology and Allergology at the Threshold of the XXI Century”, Eilat, Israel, May 3 – 6, 2000, “WHO Guidelines for Allergen Immunotherapy”.

47. Lecture Series, Kuwait, Dubai, Abu Dhabi, May 6 – 10, 2000, “Allergic Rhinitis and Sinusitis”.

48. Speaker, XVII International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 15 – 20, 2000, “Chronic Cough and GERD and Asthma”.

49. Debate adjudicator, XVII International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 15 – 20, 2000, “Does Immunotherapy Do More Harm Than Good in Asthma?”

50. Participant, postgraduate course – Immunotherapy, XVII International Congress of Allergology and Clinical Immunology, Sydney, Australia, October 15 – 20, 2000, “Practical Issues – indications, duration & dosage, a safe environment for administration”.

51. Speaker, XXVII Brazilian Congress of Allergology and Immunology, Sao Paulo, Brazil, November 11 – 15, 2000, “Osteoporosis and Asthma” and “WHO Guidelines on Immunotherapy”.

52. Guest Lecturer, 1st Nagasaki Medical Symposium, Nagasaki University School of Medicine, Nagasaki, Japan, June 2, 2001, “Update on Asthma”.

53. Guest Lecturer, Nihon University School of Medicine, Tokyo, Japan, June 6, 2001, “Asthma Treatment and Leukotriene Antagonist”.

54. Guest Lecturer, Kyoto University, Kyoto, Japan, June 7, 2001, “Asthma Treatment and Leukotriene Antagonist”.

55. Guest Lecturer, Nara University School of Medicine, Nara Japan, June 8, 2001, “Update on Asthma”.

56. Chairman, “Treatments That Might Affect This Link, Theoretical and Practical Correlations”, at the Fourth Symposium on Specific Allergen Immunotherapy, Copenhagen, Denmark. October 4-5, 2001.

58. Guest Lecturer, Peking Union Medical College Hospital, Beijing, China, “Allergen Immunotherapy”, “Acute and Chronic Sinusitis”, and “Allergic Rhinitis and Its Impact on Asthma”, (ARIA), April 5, 2002.

59. Committee Member, International Advisory Committee for World Congress on Immunopathology, December 2-6, 2002.

60. World Allergy Organization Congress XVIII ICACI, Vancouver, Canada, Sept 7-12, 2003:


65. Lockey RF, World Allergy Congress, Munich, Germany, June 26-July 1, 2005.  
   a) Debate of the Day: “Sublingual vs. subcutaneous immunotherapy-Which is better?”
   b) Satellite Symposia: Chair, “Immunotherapy with depigmented & polymerized allergen extracts product concept. clinical data & practical advantages”.
   c) Symposium 6: Chair, “Genetics of allergy”
   d) Speaker’s Corner: “How do we manage immunotherapy in asthma”
   e) Symposium 28: Anaphylaxis, “New concepts in anaphylaxis”.


69. Speaker, Joint Meeting, The XIV Latin-American Congress of Allergy, Asthma and Immunology of the Latin American Society of Allergy, Asthma and Immunology, and the XIX National Congress, organized by the Argentinean Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, August 17 - 20, 2006:
   a) Introduction (in collaboration with Prof. Carlos Baena-Cagnani)
   b) GERD and Asthma
   c) Insect Allergy
   d) Subcutaneous Immunotherapy: Efficacy and Safety
   e) Anaphylaxis: Basic Mechanism and Clinical Spectrum

70. Guest Lecturer, American College of Allergy, Asthma and Immunology (ACAAI) / Hellenic Society of Allergy and Clinical Immunology (HSACI) – Joint Allergy Symposium, Athens, Greece, September 6 – 9, 2006:

World Allergy Organization – GLORIA symposium
   a) “The Diagnosis of IgE Sensitization”
   b) “The Symptoms and Treatment of Asthma
   c) GLORIA local faculty training session

71. Guest Lecturer, Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI)/World Allergy Organization (WAO) Joint Congress 2006 & the 9th West Pacific Allergy Symposium (WPAS), Seoul, Korea, November 3 – 5, 2006, “Inhibition of RSV induced inflammation using siRNA technique”.

72. Guest Lecturer, San Paulo, Brazil, May 22 – 27, 2007:
   a) “Angioedema”
   b) “GERD and Asthma”
   c) “Asthma, COPD and Osteoporosis”

73. Guest Lecturer, II Immunotherapy Course: The Insights of Effective Vaccines for Allergy, Mexico City, Mexico, October 12 – 13, 2007:
   a) Dose Selection. PNU, BAU, AU, IR, BEAU, MCG/ML. Can We Ask for Equivalency?
   b) Anaphylaxis from ST and SIT in the Office: Prevention and Treatment.

74. Guest Lecturer, World Allergy Organization’s 20th World Allergy Congress (WAC), in partnership with The Asia Pacific Association of Allergy, Asthma & Clinical Immunology (APAAACI), The Allergy and Immunology Society fo Thailand (AIST), and the West-Pacific Allergy Organization (WPAO), Bangkok, Thailand, December 2 – 5, 2007:
   a) Historical Introduction
   b) Which allergens? (includes single vs multiple)
   c) What is new in Hymenoptera sensitivity worldwide
   d) Debate – Is SLIT first choice?

Chairperson, Oral Abstract Session – Clinical Implications of Aeroallergens
Chairperson and Introductory lecturer, Allergy Championship Final Round.

76. European Academy of Allergology and Clinical Immunology (EAACI), Barcelona, Spain, June 7 – 11, 2008:
   a) Chairperson, debate, The Ring of Pro & Con – Probiotics in the Treatment and Prevention of Atopic Diseases
   b) Symposium, Triggering Factors in Asthma: Speaker, Gastroesophageal Reflux and Asthma
   c) Speaker, Debate, The Ring of Pro & Con – Pro: Is Multiple Allergen Immunotherapy Effective?

77. Annual International Meeting - Highlights in Allergy and Respiratory Diseases, Genoa, Italy, October 30 - 31, 2008:

78. XIX World Congress of Asthma, Monte Carlo, France, November 5 – 8, 2009.
   a) Chairperson, Webinar, November 6, 2008.
   b) Guest Lecturer, November 7, 2008, “GERD and Asthma”.

79. 7th International Congress of the Egyptian Society of Pediatric Allergy & Immunology, Cairo, Egypt, February 18 – 19, 2009.
   a) Co-Chair and Lecturer, Plenary Session 1, “Update on insect allergy”
   b) Speaker, “The new NIH asthma guidelines”.

80. Guest Lecturer, Symposium – Update of Allergic Disorders (CME activity). Presented by the Hispanic American Allergy, Asthma & Immunology Association, in joint sponsorship with the American Academy of Allergy Asthma and Immunology, Washington, DC, USA, March 15, 2009, “Anaphylaxis and Allergies”.

81. Webinar lecturer, First Middle East-Asia Allergy Asthma Immunology Congress, Dubai, United Arab Emirates, March 26 – 29, 2009, “Anaphylaxis”.

82. XXVIII Congress of the European Academy of Allergology and Clinical Immunology, Warsaw, Poland, June 6 – 10, 2009:
   a) Speaker, “Immunotherapy: the American Way”
   b) Speaker, Pro & Con, “Rush versus traditional SIT (Pro).
   c) Chairperson, Clinical Plenary Symposium 2 – Aspirin exacerbated respiratory disease.

83. Guest Lecturer, 30th Annual Meeting of the Portuguese Society of Allergology and Clinical Immunology (SPAIC), Albufeira (Algarve), Portugal, October 1 – 4, 2009, “Update on Insect Allergy”.

84. XXI World Allergy Congress 2009, Buenos Aires, Argentina, December 6 – 10, 2009:
   a) Speaker, “How to use multiallergen IT"
   b) Chairperson, Symposium, "Drug allergy: Anaphylaxis and general anaesthesia"
   c) Speaker, “Anaphylaxis: Diagnosis and Treatment”
   d) Chairperson, Special Session, “Update of the NHLBI Asthma Phenotype Task Force Report”
   e) Speaker, “Aspirin-sensitive asthma, allergic asthma, and non-allergic asthma"
   f) Chairperson, Special Session, “Samuel C. Bukantz Memorial Conference”
   g) Speaker, “Early use of epinephrine”
   h) Chairperson. Special Symposium, "From Around the World: WAO, 2011"
85. Symposium: Adverse Reactions to Bovine Proteins – a Presentation of the World Allergy Organisation (WAO) Guidelines: Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA), Milan, Italy, February 4 – 6, 2010:
   a) Introduction: “The DRACMA Guidelines: a step forward in WAO’s service to allergy community” by Prof. G. Walter Canonica
   b) Guest Lecturer: “Asthma and comorbid conditions”.

86. 29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), London, United Kingdom, June 5 – 9, 2010:
   a) Guest Lecturer, “Mixing allergens: why and when”.
   b) Chair, “The ring of pro and con – Immunotherapy for asthma” (Symposium)
   c) Chair, “World Allergy Forum – Severe asthma” (Symposium)
   d) Chair, “WAO Symposium – The clinical relevance of small airways in asthma: an emerging therapeutic target”.

87. Guest Lecturer, XVIII National Congress of Allergy, Asthma & Pediatric Immunology, Monterrey, Nuevo León, Mexico, July 7 – 10, 2010:
   a) “Gastroesophageal Reflux and Asthma, Does One Exacerbate the Other?”
   b) “Adverse Effects and Fatalities Associated with Subcutaneous Allergen Immunotherapy”
   c) “Recent Advances in Insect Allergy”

88. WAO Webinar with the Georgian Association of Allergology and Clinical Immunology (GAACI), VI Georgian Congress of Allergology & Immunology, Georgia, October 1 - 3, 2010, Tbilisi – Tskhaltubo, Georgia, “Asthma and Co-Morbid Conditions”.

89. The 8th Symposium on Specific Allergy (SOSA) 2010, Paris, France, October 7 – 9, 2010:
   a) Scientific Committee
      a) Chair, “ALK Anaphylaxis symposium”
      b) Chair, “Anaphylaxis and its management

90. XVI Latin American Congress of Allergy, Asthma and Immunology, XXXVII Brazilian Congress of Allergy and Immunopathogy and CONASMA 2010 Rio de Janeiro, Brazil, November 13 – 16, 2010:
   a) Guest Lecturer, “Anaphylaxis”
   b) Guest Lecturer, “Subcutaneous immunotherapy: does it still exist”

91. World Allergy Organization (WAO) International Scientific Conference (WISC), Dubai, UAE, December 5 – 8, 2010:
   a) Speaker, “Role of bone scanning in asthma and osteoporosis”
   b) Speaker, “When and how to use epinephrine / Treatment of anaphylaxis”
   c) Speaker, “NHLBI: Asthma phenotypes”
   d) Speaker, “Asthma and comorbid conditions”
   e) Speaker, “Asthma, GERD and laryngeal pharyngeal reflex (LPR)
   f) Speaker: Treatment of anaphylaxis”
   g) Chair, Symposium – “Asthma and chest co-morbidities in the Middle East”.

92. IV World Asthma & COPD Forum, Paris, France, April 30 – May 3, 2011:
   a) Speaker, “Asthma and unusual co-morbid conditions”
   b) Speaker, “Asthma in the elderly”
93. 30th Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2011, Istanbul, Turkey, June 11 – 15, 2011:
   a) Chair, Symposium – “Current aspects of small airways in asthma”
   b) Chair, World Allergy Forum Symposium – “Urticaria: different phenotypes and diverse treatments”
   c) Chair, WAO Symposium – “Why are small airways important in asthma?”


95. Guest Lecturer, XXXIV Annual Congress, The Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, August 11 – 13, 2011:
   a) “100 years of immunotherapy”
   b) “Asthma phenotypes according to NHLBI”

96. VI World Congress on Immunopathology and Respiratory Allergy, Moscow, Russia, September 15 – 18, 2011.
   a) Co-Chair and Lecturer, Plenary Session, “Asthma and co-morbid conditions”
   b) Lecturer, “Asthma: Pathophysiology and Diagnosis”
   c) Workshop on “Skin Testing”
   d) Literature Review and/Summary

97. XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011:
   a) Presidential Address, WAO Presidential Plenary Session
   b) Speaker, “Overview of comorbid conditions”
   c) Speaker (welcoming remarks), 1st WAO Allied Health Session – Asthma: Diagnosis, management and education.
   d) Chairperson, Specific Immunotherapy (SIT): History, mechanisms and future.
   e) Chairperson, Specific immunotherapy (SIT).
   f) Chairperson, Specific Immunotherapy (SIT): Which patients for SIT and anti-IgE?”

98. Adjuvant 2012 & Allergen Vaccines 2012 International Conference, Varadero, Cuba, May 6 – 11, 2012:
   a) Opening Lecture, “Asthma, a syndrome of multiple phenotypes and co-morbidities”
   b) Speaker, “SCIT practice parameters”.

99. Xth Latin-American Congress of Immunology, IMMUNOPERUU 2012, Lima, Peru, May 29 – June 2, 2012:
   a) Lecturer, “Immunotherapy of Asthma”
   b) Lecturer, “Asthma, a Syndrome of Different Phenotypes and Comorbidities”

100. Chair, “House Dust Mite Allergy”, at the 9th Symposium on Specific Allergy 2012 (SOSA 2012), Berlin, Germany, September 27 – 29, 2012.

101. XVII Congress of the Latin American Society of Allergy, Asthma and Immunology (SLaai), Cartagena, Columbia, October 24 – 27, 2012:
   a) Lecturer, “Hymenoptera Stings Allergy – Clinical and Diagnostic Aspects”
   b) Lecturer, “Anaphylaxis – WAO Guidelines”
102. 2012 WAO International Scientific Conference (WISC 2012), Hyderabad, India, December 6 – 9, 2012:
   a) Understanding and recognizing anaphylactic reactions
   b) Selection and preparation of Allergen Extrats
   c) Gastroesophageal Reflux Disease (GERD)
   d) Mechanisms of Anaphylaxis

103. European Academy of Allergy and Clinical Immunology (EAACI) and World Allergy Organization (WAO) - World Allergy & Asthma Congress, Milan, Italy, June 22 – 26, 2013”
   a) Speaker, “Meet the Expert – Comorbidities of asthma”
   b) Chair – poster discussion session, “Novel Mechanisms in Allergen-Specific Immunotherapy: New Molecules and New Routes”

104. National Congress of Pediatric Allergy and Asthma, Cyprus, Turkey, April 23-26, 2014, “Allergen Immunotherapy: Sublingual and Subcutaneous; Efficacy, Indications and Precautions”.

BIBLIOGRAPHY:

BOOKS:


5. Fink JN, Lockey RF (eds): Medical Knowledge Self-Assessment Program in the subspecialty of Allergy and Immunology (MKSAP-AI). Developed by the American Academy of Allergy, Asthma and Immunology and the American College of Physicians. American College of Physicians, Independence Mall West, Sixth Street at Race, Philadelphia, PA 19106-1572 (300 pages).


BOOKS IN SPANISH:


BOOKS TRANSLATED IN SPANISH:


Collaborator/Contributor
of BOOKS PUBLISHED:


2. Lockey RF, contributor, Section on Allergy and Immunology, The Consultation Guide, Paul W. Ladenson, M.D.(ed), Lippincott Williams & Wilkins, Baltimore, Maryland, 1999, pp 1-29.


MONOGRAPHS:


INTERNET PUBLICATIONS:
( Editor)


INTERNET PUBLICATIONS:

(Author)


Include:

0 Allergic rhinitis, adult 0 Atopic dermatitis
0 Allergic Wor, pediatric 0 Allergic contact dermatitis
0 Vasomotor rhinitis 0 Acute urticaria
0 Gustatory rhinitis 0 Chronic urticaria
0 NARES 0 Angioedema without urticaria
0 Nasal polyps 0 Allergen Immunotherapy
0 Acute sinusitis, adult 0 Anaphylaxis
0 Acute sinusitis, pediatric 0 Stinging insect allergy
0 Chronic sinusitis, adult 0 Food allergy
0 Chronic sinusitis, pediatric 0 Drug allergy
0 Acute asthma, adult 0 Latex allergy
0 Acute asthma, pediatric 0 Allergic conjunctivitis
0 Asthma, chronic management, adult 0 Allergen avoidance
0 Asthma, chronic management, pediatric
0 Asthma during pregnancy
0 Exercise-induced asthma
5. Lockey RF, Reichmuth D: “Allergic Reactions to Insect and Arthropod Bites and Stings”. In: Gotto A (ed.) DISEASEDEX ™ General Medicine, October 25, 2002. MICROMEDEX, Greenwood Village, CO: www.mdx.com


28. Aljubran SA, Lockey RF:


EXPERIMENTAL PAPERS:


7. Lockey RF:
   Urticaria of unknown origin.
   Hospital Practice 14:49-54, 1979.

8. Lockey RF:
   Cost of testing and treating with Hymenoptera venom extracts.

9. Schwartz HJ, Lockey RF, Sheffer AL, Parrino J, Busse WW, Yunginger JW:
   A multi-center study on skin test reactivity of human volunteers to venom as
   compared to whole body Hymenoptera antigens.

10. Lockey RF, Stablein JJ, Binford LRF:
    Melaleuca tree and respiratory disease. Allergen or irritant effect of melaleuca
    pollen and odor, respectively, in patients with allergic and respiratory disease.

11. Parrino J, Kandawalla NM, Lockey RF:
    Treatment of local skin response to imported fire ant sting.

12. Asai S, Krzanowski JJ, Anderson WH, Martin DF, Polson JB, Lockey RF, Bukantz SC, Szentivanyi A:
    Effects of the toxin of red tide on Ptychodiscus brevis canine tracheal smooth
    muscle (a possible new asthma-triggering mechanism).

13. Lockey RF:
    Letter to editor, Refractory period to aspirin after aspirin-induced asthma.

14. Fox RW, Lockey RF, Bukantz SC:
    Neurologic sequelae following the imported fire ant sting.

15. Fox RW, Samaan SS, Bukantz SC, Lockey RF:
    Theophylline kinetics in a geriatric group.

16. Stablein JJ, Samaan SS, Bukantz SC, Lockey RF:
    Pharmacokinetics and bioavailability of three dyphylline preparations.

17. Fox RW, Samaan SS, Lockey RF, Bukantz SC:
    A study of oxtriphylline SA in fifty asthmatics.


30. Weiss A, Ledford D, Lockey RF:  
Toxoplasmic retinochoroiditis as an initial manifestation of acquired immune deficiency syndrome.  

31. Nelson RP, Ledford DK, DeVoep PW, Lockey RF:  
The use of hepatitis hyperimmune globulin in healthcare workers exposed to HTLV-III. Letter.  

Workshop 5: Assessment of efficacy task force on guidelines for clinical investigation of nonbronchodilating anti-asthmatic drugs.  

33. Fox RW, Lockey RF, Bukantz SC, Serbousek D:  
Treatment of chronic idiopathic urticaria with astemizole.  

34. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC:  
Fatalities associated with immunotherapy and skin testing.  

Comparison of inhaled albuterol powder and aerosol in asthma.  

Australian pine (*Casuarina equisetifolia*) pollen as an aeroallergen.  

37. Minor MW, Lockey RF, Fox RW:  
Mekkersson-Rosenthal Syndrome.  

38. Shimoda T, Krzanowski J, Lockey RF, Martin DF, Perez-Cruet M, Polson J, Duncan R:  
Lower canine airway smooth muscle contraction induced by *Ptychodiscus brevis* (red tide) toxin.  

39. Ganguly R, Khakoo RA, Desai V, Lockey RF:  
Aging and local immunity against respiratory tract infection.  

40. Diaz JD, Berman A, Lockey RF, Espinoza LR:  
Classification systems for human immunodeficiency virus (HIV) infection. Letter.  
41. Watanabe T, Lockey RF, Krzanowski JJ:
Airway smooth muscle contraction induced by Ptychodiscus brevis (red tide) toxin as related to a trigger mechanism of bronchial asthma.

42. Shimoda T, Krzanowski J, Nelson R, Martin D, Polson J, Duncan R, Lockey R:
In vitro red tide toxin effects on human bronchial smooth muscle.

43. Berman A, Espinoza L, Diaz J, Rolando T, Vasey F, Germain B, Lockey R:
The rheumatic manifestations of human immunodeficiency virus infection.

44. Lockey RF, Turkeltaub PC, Baird-Warren, IA, Olive CA, Olive ES, Peppe BC, Bukantz SC:
The Hymenoptera venom study, I, 1979-1982, demographics and history sting data.

45. Nordvall SL, Johansson SGO, Ledford DK, Lockey RF:
Allergens of the imported fire ant.

46. Polson J, Lockey R, Bukantz S, Lowitt S, Krzanowski J, Szentivanyi A:
Effects of ketotifen on the responsiveness of peripheral blood lymphocyte beta adrenergic receptors.

47. Watanabe T, Duncan R, Lockey RF, Krzanowski Jr., JJ:
Histamine tachyphylaxis in young dog airway - compared with adult dog.

48. Diaz JD, Nelson RP, Lockey RF:
IgG subclass deficiency and recurrent infections.

49. Ledford DK, Sakamoto Y, O'Connor C, Krzanowski K, Lockey RF, Polson J, Krzanowski J:
Lack of effect of gold salts on acetylcholine or histamine contraction of canine tracheal and bronchial smooth muscle.

Loratidine (SCH 29851) 20 mg od versus clemastine 1 mg bid in the treatment of perennial allergic rhinitis.

51. Lockey RF, Turkeltaub PC, Olive CA, Baird-Warren I, Olive ES, Bukantz SC:
The Hymenoptera venom study, II, skin test results and safety of venom skin testing.


63. Russell DW, Fernandez-Calidas E, Trudeau WL, Swanson MC, Seleznick MJ, Lockey RF:
   Caffeine, a natural acaricide.

64. Schou C, Fernandez-Calidas E, Lockey RF, Lowenstein H:
   Environmental assay for cockroach allergens.

65. Calderon E, Lockey RF:
   Methotrexate in bronchial asthma.

66. Silton RP, Fernandez-Calidas E, Trudeau W, Swanson MC, Lockey RF:
   Prevalence of specific IgE to the storage mite *Aleuroglyphus ovatus*.

67. Garcia-Ramos Alonso E, Fernandez-Calidas E, Lockey RF:
   Prevalencia de pruebas cutaneas positivas a 22 alergenos en lapoblacion juvenil de Tenerife, Islas Canarias, Espana.

68. Bucholtz GA, Lockey RF, Binford LRF, Wunderlin RP, Stablein JJ, Serbousek D, Fernandez-Calidas E:
   A three-year aerobiologic pollen survey of the Tampa Bay Area, Florida.

69. Puerta Llerena L, Fernandez-Calidas E, Carballo Gracia LR, Lockey RF:
   Sensitization to *Blomia Tropicalis* and *Lepidoglyphus destructor* in *Dermatophagoides* spp. allergic individuals.

70. Russell DW, Cameron DJ, Lockey RF, Behnke RH, Sinnott JT, Ganguly R:
   Influenza vaccine acceptance among health care professionals.

71. Garcia-Ramos Alonso E, Fernandez-Calidas E, Seleznick MJ, Lockey RF:
   Respiratory allergies and skin test reactivity in high school students in Tenerife, Canary Islands, Spain.

   Cysteine and serine proteinases in extracts of the storage mite, *Aleuroglyphus ovatus*.

73. Jacinto CM, Nelson RP, Bucholtz GA, Fernandez-Calidas E, Trudeau WL, Lockey RF:
   Nasal and bronchial provocation challenges with bayberry (*Myricagerifera*) pollen extract.


97. Stanaland BE, Fernandez-Caldas E, Jacinto CM, Trudeau WL, Lockey RF: Positive nasal challenge responses to _Blomia tropicalis_. 


100. Nelson RP, DiNicolo R, Fernandez-Caldas E, Seleznick MJ, Lockey RF, Good RA: Allergen specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. 


103. Puerta L, Caraballo LR, Fernandez-Caldas E, Avjioglu A, Marsh DG, Lockey RF, Dao ML: Nucleotide sequence analysis of a complementary DNA Coding for a _Blomia tropicalis_ allergen. 
104. Kemp SF, Lockey RF:  

105. Kemp SF, Lockey RF:  
Peanut anaphylaxis from food cross-contamination.  

106. Codina R, Calderon E, Lockey RF, Fernandez-Caldas E, Rama R:  
Specific immunoglobulins to soybean hull allergens in soybean asthma.  

107. Rizzo MC, Naspitz CK, Fernandez-Caldas E, Lockey RF, Mimica I, Solé D:  
Endotoxin exposure and symptoms in asthmatic children.  

108. Codina R, Lockey RF, Fernandez-Caldas E, Rama R:  
Purification and characterization of a soybean hull allergen responsible for the Barcelona asthma outbreaks. II. Purification and sequencing of the Gly m 2 allergen.  

109. Kemp SF, Lockey RF, Fernandez-Caldas E, Arlian LG:  
Skin test and crossreactivity studies with *Euroglyphus maynei* and *Dermatophagoides pteronyssinus*.  

110. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM and the Zafirlukast Trialists Group:  
Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study.  

111. Fernandez-Caldas E, Andrade J, Trudeau WL, Souza Lima E, Souza Lima I, Lockey RF:  
Serial determinations of *Der p 1* and *Der f 1* show predominance of one *Dermatophagoides* species.  

112. Codina R, Lockey RF:  
Possible role of molds as secondary etiologic agents of the asthma epidemics in Barcelona, Spain.  

113. Behera AK, Kumar M, Matsuse H, Lockey RF, Mohapatra SS:  
Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells.  

114. Codina RM, Oehling AG, Lockey RF:  
Neoallergens in heated soybean hull.  


155. Kuderer N, San Juan Vergara, HG, Kong X, Lockey RF, Mohapatra SS: Mite and cockroach proteases activate p44/p42 MAP kinases in human lung epithelial cells, *Clinical & Molecular Allergy*, 1:1, 2003 [www.clinicalmolecularallergy.com/content/1/1/1](http://www.clinicalmolecularallergy.com/content/1/1/1)


166. Lockey RF: (contributor): Osborne M, Deffebach M:

Serum total IgE and specific IgE to *Dermatophagoides pteronyssinus*, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. *Allergy Asthma Proc* 2004; 25(5): 321-5.

Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. *Ann Allergy Asthma Immunol* 2005; 95: 247-253.


170. Lockey RF: (contributor):


172. San Juan Vergara HG, Cuevas J, Lockey RF, Mohapatra SS:

173. Kong X, Hellermann GR, Patton G, Kumar M, Behera A, Randall TS, Zhang J, Lockey RF, Mohapatra SS:


185. Vu AT, Lockey RF:  

186. Lee DW, Shirley S, Lockey RF, Mohapatra SS:  

187. Kearney DM, Lockey RF:  

188. Lockey RF (contributor as principal investigator):  
Dixon A, Kaminsky D, Holbrook J, Wise R, Shade D, Irvin C:  
Allergic rhinitis and sinusitis in asthma: Differential effects on symptoms and pulmonary function. *Chest* 2006;130: 429-35.

189. Lockey RF (contributor as principal investigator):  

190. Lockey RF (contributor as principal investigator):  

191. Lee D, Lockey RF, Mohapatra SS:  

192. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra SS:  

193. Lockey RF (Contributor):  
Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA for the TENOR Study Group:  

194. Lockey RF (Contributor):  
Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H, Wenzel SE, Weiss ST for the TENOR Study Group:  

195. Lockey RF (Contributor):  
The American Lung Association Asthma Clinical Research Centers:  


208. Wang X, Xu W, Mohapatra S, Kong X, Xu L, Lockey RF, Mohapatra S:
   http://www.gvt-journal.com/content/6/1/7

209. Codina R, Fox RW, Lockey RF, DeMarco P, Bagg AS:


211. Esch RE, Bush RK, Peden D, Lockey RF:

212. King MJ, Tamulis T, Lockey RF:

213. Shirley SA, Montpetit AJ, Lockey RF, Mohapatra SS:
   Curcumin prevents human dendritic cell response to immune stimulants. *Biochemical and Biophysical Research Communications* 2008; 374:431-436.


215. Karpel J, D’Urzo A, Lockey RF:


38
217. Lockey RF (Contributor):

218. Lockey RF (Contributor):
The American Lung Association Asthma Clinical Research Centers:

219. Bagg A, Chacko T, Lockey RF:
Systemic reactions to prick and intradermal skin tests. *Annals of Allergy, Asthma & Immunology* 2009; 102(5):400-402


221. Casale TB, Canonica GW, Bousquet J, Cox L, Lockey RF, Nelson HS, Passalacqua G:

222. Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, McFadden ER, Pixton GC, Barrett RJ:

223. Lockey RF (Contributor):

224. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S, Mohapatra SS:

225. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G:

226. Shin B, Cole S, Park Sang-Joon, Ledford DK, Lockey RF:

227. Phillips JF, Jelks ML, Lockey RF:
228. Kandasamy R, Park SJ, Boyapalle S, Mohapatra S, Hellermann G, Lockey RF, Mohapatra SS:

229. Rael E, Ramey J, Lockey R:

230. Phillips JF, Fox RW, Ledford DK, Glaum M., Lockey RF:


232. Kim D, Phillips J, Lockey RF:

233. Lockey RF (Contributor):
Writing Committee for the American Lung Association Asthma Clinical Research Centers:
Lansoprazole for children with poorly controlled asthma. *JAMA* 2012; 307(4): 373-381.

234. Aljubran SA, Cox R, Parthasarathy PT, Ramanathan GK, Rajanbabu V, Bao H, Mohapatra SS, Lockey RF, Kolliputi N:

235. Kolliputi N, Galam L, Parthasarathy PT, Tipparaju SM, Lockey RF:

236. Westermann-Clark E, Fitzhugh D, Lockey RF:
Increasing cost of epinephrine autoinjectors. *JACI* 2012; 130(3): 822-823.


238. Elizalde A, Perez EE, Sriaaroon P, Nguyen D, Lockey RF, Dorsey MJ:
Intensive educational course in allergy and immunology. *Allergy* 2012; 67(9): 1085-6.
239. Lockey RF (Contributor) 
Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei C, et al., for the American Lung Association Asthma Clinical Research Centers: 


244. Desai P, Tamarapu Parthasarathy P, Galam L, Lockey R, Kolliputi N: 

245. Lane T, Flam B, Lockey R, Kolliputi N: 

246. Qazi O, Parthasarathy PT, Lockey R, Kolliputi N: 

247. Fukumoto J, Lockey R, Kolliputi N: 

248. Lockey RF (contributor): 
Lang JE, Dozor AJ, Holbrook JT, et al., for the American Lung Association – Asthma Clinical Research Centers: 


256. Pepper AN, Lockey RF, Glaum MC: Lymphopenia induced by etanercept. *Annals of Allergy, Asthma and Immunology*, accepted for publication.


REVIEWS, INVITED ARTICLES and EDITORIALS:


4. Lockey RF, Bukantz SC:  
   Allergic emergencies  

5. Lockey RF:  
   Quality, not quantity.  

6. Lockey RF:  
   The paradox of medical regulation.  

7. Lockey RF:  
   The clinical examination, good cost-effective medicine.  

8. Lockey RF:  
   Food allergy: a clinical approach.  

9. Lockey RF:  
   The laetril syndrome.  

10. Bukantz SC, Lockey RF:  
    Controversial techniques, protocols for evaluation.  
    *Hospital Practice* 16(7):11-12, 1981.

11. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  

12. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  
    *Patient Care* 15 (18), Part IV, pp 63-98, 1981.

13. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  
    *Patient Care* 15 (19), Parts V, VI, pp 115-186, 1981.

14. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  

15. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  
    *Patient Care* 16 (2), Parts VIII, IX, pp 105-151, 1982.

16. Lockey RF:  
    Participant in asthma roundtable, parts I-X.  
17. Lockey RF:
   Allergic mechanisms.

18. Lockey RF:
   Reviewer's comments, devising a bronchodilator therapy plan.
   *Patient Care* 17:60-63, 1983.

19. Lockey RF:
   Stinging insect allergy.

20. Lockey RF:
   Management of anaphylactic reaction to bee sting.

21. Stablein JJ, Lockey RF:
   Managing asthma during pregnancy.

22. Nelson RP, Stablein JJ, Lockey RF:
   Asthma improved by acetylsalicylic acid and other nonsteroidal anti-inflammatory agents.

23. Lockey RF:
   Wild carrot allergy.

24. Lockey RF, Bukantz SC:
   Allergy and immunology.

25. Lockey RF, Bukantz SC:
   Allergy and immunology.

26. Lockey RF, Bukantz SC:
   Allergy and immunology.

27. Lockey RF, Bukantz SC:
   Allergy and immunology.

28. Bukantz SC, Lockey RF:
   Machiavelli and medicine: a bad mixture.

29. Lockey RF:
   Some truths about animal research.
30. Lockey RF:
   Asthma: minimizing hospitalization.

31. Lockey R:
   Iodine allergy: is any iodine containing solution safe?
   Questions and Answers.

32. Stablein JJ, Lockey RF:
   Adverse reactions to ant stings.

33. Minor M, Lockey RF:
   Sinusitis and asthma.

34. Sakamoto Y, Lockey RF, Krzanowski J Jr:
   Shellfish and fish poisoning related to the toxic dinoflagellates.

35. Nelson RP, Ledford DK, Lockey RF:
   The epidemiology of AIDS.

36. Nelson RP, Lockey RF:
   Current treatment for patients with severe asthma.

37. Bernstein IL (Ed.), Lockey RF (contributing author):
   Proceedings of the task force on guidelines for standardizing old and new technologies used for the diagnosis and treatment of allergic diseases.

38. Lockey RF, Bukantz SC:
   Fatalities associated with skin testing and immunotherapy.

39. Sheffer AL, Lieberman PL, Aaronson DW, Anderson JA, Kaplan AP, Pierson WE, Ellis EF, Lichtenstein LM, Lockey RF, Salvaggio JE, Zweiman B:
   Measurement of circulatory IgG and IgE food-immune complexes.

40. Nelson R, Lockey RF:
   Treatment of asthma with glucocorticosteroids.

41. Lockey R, Bukantz S, Turkeltaub P:
   Fatalities associated with skin testing and immunotherapy.
42. Wunderlin RP, Lockey RF:  
Is goldenrod a source of aeroallergens? Questions and Answers.  

43. Wright DN, Lockey RF:  
Adverse and allergic reactions to ant stings in U.S.A.  

44. Lockey RF, Bukantz SC:  
Fatalities associated with skin testing and immunotherapy.  
*Pediatric Asthma, Allergy and Immunology* 2:149-150, 1988.

45. Nelson RP, Lockey RF:  
How you can control asthma triggers.  

46. Lockey RF:  
Animals in education.  
The *Bulletin*, of the Hillsborough County Medical Association  

47. Nelson RP, Lockey RF:  
How to watch out for worsening asthma.  
*J Resp Dis* 10(4), April, 1989.

48. Silton RP, Ledford DK, Lockey RF:  
A promising new drug for severe asthma.  

49. Lockey RF, Bukantz SC:  
Allergy and immunology.  

50. Wright DN, Lockey RF:  
Defusing beta-lactam allergy.  

51. Lockey RF, Fox RW, Ledford DK:  
What is allergy?  

52. Lockey RF:  
Response to Dr. Catlett.  

53. Lockey RF:  
Cytotoxic and immune complex reactions.  

54. Lockey RF, Bukantz SC:  
Allergy and immunology (*Alergija i imunologija*).  


67. Fernandez-Caldas E, Lockey RF:

   The importance of environmental changes to control mite allergens.
   Current Issues in Allergy and Immunology, 1(1):18-21, 1990.

68. Lockey RF:

   Immunotherapy for allergy to insect stings.
   Guest editorial.

69. Calderon EG, Lockey RF:

   Nutritional disorders in HIV disease.

70. Lockey RF:


71. Lockey RF, Calderon E:

   Mechanisms of hypersensitivity injury.

72. Bukantz SC, Lockey RF:

   Allergy and immunology

73. Settipane, Guy A.:


74. Garcia-Ramos Alonso, Lockey RF:

   Treatment concepts for HIV infection.

75. Garcia-Ramos Alonso, Lockey RF, Bukantz SC:

   Eosinophils and eosinophilia.

76. Lockey RF, Bukantz SC:

   Questions and answers, seawater-induced itching.

77. Calderon E, Lockey RF, Bukantz SC, Coffey R, Ledford DK:

   Is there a role for cyclosporine in asthma?

78. Ganguly R, Lockey RF:

   Taking better advantage of hepatitis B immunoprophylaxis.

79. Edwards TB, Lockey RF:

   Gold for asthma?
80. Fernandez-Caldas E, Lockey RF:
   The hidden menace of indoor allergens.


82. Jacinto CM, Lockey RF:
   Relieving idiopathic chronic urticaria/angioedema.

83. Lockey RF, Bukantz SC:
   Allergy and immunology.

84. Nelson RP, Lockey RF:
   Patient education guide: avoiding "triggers" of asthma.

85. Lockey RF:
   President's message: reorganization and many new programs underway.
   *American Academy of Allergy and Immunology News and Notes*
   Volume 92 Issue Two, pp 5-6, 1992.

   Position statement: The use of in vitro tests for IgE antibody in the specific
diagnosis of IgE-mediated disorders and in the formulation of allergen
immunotherapy.

87. Stewart GE, Lockey RF:
   Editorial: Systemic reactions from allergen immunotherapy.

88. Lockey RF:
   "Dear pharmacists" letter.

89. Lockey RF:
   Future trends in allergy and immunology.
   Primer on Allergic and Immunologic Diseases.

90. Lockey RF:
   Tell your patients, friends and representatives why they should support animal
research.

91. Lockey RF:
   President's message: the Academy prepares for the twenty-first century.
   *American Academy of Allergy and Immunology News and Notes*, 3:5-6, 1992.
92. Lockey RF:
   Letter from president: treat every person as if they were your mother or father. 
   *American Academy of Allergy and Immunology Fellows In Training Newsletter*, 

93. Calderon E, Lockey RF:
   A possible role for adhesion molecules in asthma. 

94. Hilman BC, Wasserman S, Lockey RF, Buckley CE:
   Workshop D: present status and future issues/directions of allergy and immunology 
   training programs/academic centers. 

95. Ganguly R, Lockey RF:
   Minimizing the severity and complications of herpes zoster. 

96. Lockey RF:
   The Academy reorganizes on its fiftieth anniversary. 
   *J Allergy Clin Immunol* 91:3-6, 1993.

97. Nelson RP, Lockey RF, Bukantz SC:
   Signs of an impending attack-and steps to counterattack. 

98. Spectrum Healthcare Professional Publishing:
   The contribution of cell adhesion molecules to asthma and immunology basics. 
   *Clinical Immunology Spectrum* 5:6-8, 1993.

99. Lockey RF:
   Letter Response to Dr. Wantke: Reduction of side effects of specific immunotherapy. 

100. Ganguly R, Lockey RF:
   It's the season for flu shots. 

101. Lockey RF:
   American Academy of Allergy and Immunology Presidential Address: 
   The Academy: The past, present and future. 

102. Stanaland BE, Lockey RF:
   Allergy to ants. 
   *American Academy of Allergy and Immunology Fellows-in-Training Newsletter*, 

103. American Academy of Allergy and Immunology Board of Directors:
   Guidelines to minimize the risk from systemic reactions caused by immunotherapy 
   with allergenic extracts. 
104. Ledford DK, Lockey RF:
   Building- and home-related complaints and illnesses: "Sick Building Syndrome".

105. Lockey RF:
   Building- and home-related complaints and illnesses: summary statement.

106. Kemp SF, Lockey RF:
   Anaphylaxis: an overview.

107. Lockey RF, Fox RW, Ledford DK:
   What allergists say about allergy...
   In *People Living with Allergies Year-round*.
   A Marion Merrell Dow, Inc. bulletin.

108. Lockey, RF:
   The future of allergy and immunology, amalgamation of societies and standard forms for skin testing and immunotherapy.

109. Lockey, RF:
   Commentary: AAAI proposed fall meeting

110. Fernandez-Caldas E, Lockey RF:
   *Blomia tropicalis* - a mite of clinical importance.

111. Lockey RF:
   Reply to: 1) At-home administration of allergenic extracts by Falliers CJ.
   2) Home allergenic extract administration by Wells JH.

112. Stewart GE, Lockey RF:
   Applications for IV immunoglobulin therapy.

113. Lockey RF:
   Book review - "Taming asthma and allergy by controlling your environment: a guide for patients" by Robert A. Wood, M.D.

114. Lockey RF:
   Adverse reactions associated with skin testing and immunotherapy.

115. Lockey RF:
   Management of chronic sinusitis.
   *Hospital Practice*, 31(3):141-151, March 1996.
116. Wasserman SI, Austen KF, Lockey RF:
Board requirements versus National Institutes of Health requirements.

117. Kemp SF, Lockey RF:
Aspartame as a cause of allergic reactions, including anaphylaxis.
(Reply).

118. Zhaoming W, Lockey RF:
A review of allergic bronchopulmonary aspergillosis.

119. Lockey RF:
Allergy and Immunology Training in Florida: Current and Future.

120. Developed by The Joint Task Force on Practice Parameters representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology.
Reviewers: Condemi JJ, Dykewicz M, Fineman SM, Hannaway PJ, Lockey RF, Nicholas SS, Reid MJ, Shapiro GG, Wood RA:
Practice parameters for allergen immunotherapy.

121. Lockey RF (participant):
Supplement: American Thoracic Society workshop achieving healthy indoor air,

122. Kasti G, Lockey RF:
Disease prevention: which nutritional supplements, vitamins, and medications may help?

123. Lockey RF:
The Basic principles of asthma management today.

124. Kasti G, Lockey RF:
Latest recommendations on folate and B₆ intake for women.

125. Ledford DK, Lockey RF:
Allergic rhinitis: Understanding the process.

126. Ledford DK, Lockey RF:
Allergic rhinitis: Offering relief this season.
127. Bousquet J, Lockey RF, Malling HJ (eds):
    WHO Position Paper
    Allergen immunotherapy: therapeutic vaccines for allergic diseases.

128. Bousquet J, Lockey RF, Malling HJ (eds) and the WHO panel members:
    Allergen immunotherapy: Therapeutic vaccines for allergic diseases - A WHO
    position paper.

129. Bousquet J, Lockey RF, Malling HJ (eds) and the WHO paper, an executive summary
    Allergen immunotherapy: Therapeutic vaccines for allergic diseases.

130. Codina R, Lockey RF:
    How to earn a PhD in the U.S.
    European Academy of Allergy and Clinical Immunology (EAACI)

131. Lockey RF:
    News from the U.S.
    European Academy of Allergy and Clinical Immunology (EAACI)

132. Theodoropoulos DS, Lockey RF, Boyce Jr., HW, Bukantz SC:
    Gastroesophageal reflux and asthma: a review of pathogenesis, diagnosis, and
    therapy.

133. Theodoropoulos DS, Lockey RF, Boyce Jr., HW:
    Sandifer’s syndrome and gastroesophageal reflux disease.

134. Lockey RF, Codina R:
    Environmental control and the consumer.

135. Lockey RF, Mohapatra SS:
    The search for clues to wheeze, itch, sneeze and cough.

136. Lockey RF:
    News from the EAACI (Cooperation, collaboration evident between U.S. and
    European associations).
    *Academy News (American Academy of Allergy, Asthma and Immunology)*,

137. Lockey RF, Bousquet J, Malling HJ:
    Reply (letter to editor) to article by Morris DL entitled, “WHO position paper on
    oral (Sublingual) immunotherapy”.
138. Lockey RF:
   News from the EAACI (EAACI to meet in Lisbon).

139. Lockey RF:
   Physicians must demand “What is Scientifically and Morally Right” and reject expediency.
   (Editorials/Letters/Commentary).

140. Codina R, Lockey RF:
   Combating allergens at home: What you need to know about preventing asthma.

141. Codina R, Lockey RF:
   Environmental Asthma: Nine questions physicians often ask.

142. Reichmuth DA, Lezama JL, Adelman HM:
   Lockey RF (Section Editor, Allergy and Immunology):
   Abdominal pain and diarrhea after minor trauma.

143. Theodoropoulos DS, Ledford DK, Lockey RF:
   Reply (letter to editor) to article by Crisera CA, Connelly PR, et al, entitled, “TTF-1 and HNF-3beta in the developing tracheoesophageal fistula: further evidence for the respiratory origin of the distal esophagus”.

144. Lockey RF:
   News from the EAACI (Training standards to be adopted in EU)
   Academy News (American Academy of Allergy, Asthma and Immunology), 6(4):31, April 2000.

145. Bousquet J, Lockey RF, Malling HJ:
   Allergen immunotherapy: Therapeutic vaccines for allergic diseases – A WHO position paper.

146. Lockey RF:
   News from the EAACI (President’s goals include increased representation)
   Academy News (American Academy of Allergy, Asthma and Immunology), 6(6):33, June 2000.

147. Theodoropoulos DS, Lockey RF:
   Allergen immunotherapy: Guidelines, update and recommendations of the World Health Organization.
   Allergy and Asthma Proc, 21(3):159-166, 2000.

148. Reichmuth D, Lockey RF:
   How to proceed when you suspect rhinosinusitis.
149. Reichmuth D, Lockey RF:
   How to provide effective treatment for rhinosinusitis.

150. Lockey RF:
   News from the EAACI (EAACI XIXth Congress showcases new research)
   *Academy News* (American Academy of Allergy, Asthma and Immunology), 6(9):24, September 2000.

151. Lockey RF:
   News from the EAACI (Bachert strives for excellence as newsletter editor)

152. Lockey RF (participant):
   Prevention of allergy and asthma interim report. (Based on the WHO/IAACI Meeting on the primary prevention of allergy and asthma, Geneva, Switzerland, December 5-6, 1999).

153. Reichmuth D, Lockey RF:
   Present and potential therapy for allergic rhinitis: a review.

154. Ramirez N, Lockey RF:
   Putting nocturnal asthma to rest.
   *Advance for Managers of Respiratory Care*, 10(3), 47-50, March 2001

155. Lockey RF:
   News from the EAACI (EAACI congress set in Berlin)

156. Lockey RF:
   News from the EAACI (EAACI to sit on WAO nominating committee)

   Ethics in allergy

158. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC:
   Systemic reactions and fatalities associated with allergen immunotherapy.

159. Hoppe C, Lockey RF:
   News from national societies.

160. Lockey RF:
   “ARIA”: Global guidelines and new forms of allergen immunotherapy”.
161. Lockey RF, Codina R (contributing reviewers):
   Guidelines for the control of indoor allergen exposure.

162. Mohapatra SS, Lockey RF:
   Molecular characterization of allergens.

163. Ramirez NC, Lockey RF:
   Putting nocturnal asthma to rest. Advance for managers for respiratory care 2001; 47-8, 50 (online edition: [www.advanceformrc.com](http://www.advanceformrc.com)).

164. Lockey RF:
   News From the EAACI, “Van Cauwenberge assumes EAACI presidency”, [Providing regular updates from the European Academy of Allergology and Clinical Immunology (EAACI) and the practice of allergy/immunology abroad].
   *Academy News* (American Academy of Allergy, Asthma and Immunology), 7(9):36, October, 2001.

165. Lockey RF:

166. Lockey RF:
   News from the EAACI (Meet EAACI’s executive committee), part 1.

167. Lockey RF (co-author):
   Management of allergic rhinitis and its impact on asthma: A pocket guide for physicians and nurses 2001 (translated into 50 languages)
   Part of ARIA Initiative – in collaboration with World Health Organization (WHO)

168. Lockey RF:

169. Lockey RF:
   How now, brown cow, vaccine or extract? *Current Allergy and Asthma Reports* 2002, 2:181-182.

170. Lockey RF:

171. Lockey RF:
   News from the EAACI (Meet the officers of the EAACI’s executive committee), part II.
172. Lockey RF:  
World Allergy Organization (WAO) represents specialty worldwide.  

173. Kemp SF, Lockey RF:  

174. Lockey RF:  

175. Lockey RF:  

176. Lockey RF:  
Commentary by Lockey RF (AAAAI position statement #19 revision for member comment The wait period after allergen immunotherapy and skin testing) _Academy News_ (American Academy of Allergy Asthma & Immunology), 8(9):29:October 2002.

177. Lockey RF: (2002 revision drafted):  
American Academy of Allergy Asthma & Immunology, Position statement, adrenergic blockers, allergen immunotherapy and skin testing. 2002.

178. Theodoropoulos DS, Lockey RF:  

179. Bousquet J (ed) Lockey RF (one of 18 contributors):  
Management of allergic rhinitis symptoms in the pharmacy, “ARIA in the Pharmacy”, allergic rhinitis and its impact on asthma, in collaboration with the WHO, 2003.

180. Bousquet J (ed) Lockey RF (one of 18 contributors):  

181. Lockey RF: (participant)  

182. Lockey RF:  
Corresponding Editor for the EAACI Newsletter by editorial staff (Paris will host 22nd EAACI congress in June), _Academy News_ Vol: 9(1), Jan 2003.

183. Lockey RF, Hoppe C:  
News from the EAACI (AAAAI 60th anniversary meeting looks back on 60 years of progress). _Academy News_ Vol: 6(1) 2003.
184. Lockey RF:

185. Lockey RF:

186. Lockey RF, Contributor:
   Requirements for medications commonly used in the treatment of allergic rhinitis, Allergy 2003:58:192-197.

187. Li JT, Lockey RF, Bernstein IL, et al.

188. Li JT, Lockey RF, Bernstein IL, et al (eds)

189. Lockey RF, Corresponding Editor and Oleg Tsinkalovsky:

190. Lockey RF:

191. Lockey RF (Edited):

192. Fox RW, Lockey RF:

193. King MJ, Lockey RF:

194. Lockey RF:

195. Lockey RF:

196. Lockey RF:


209. Codina R, Lockey RF:

210. DeMarco PJ, Lockey RF:

211. Lockey RF, Corresponding Editor:

212. Kearney DM, Lockey RF (ed), introduction:
From Allergen to Asthma: Points for Intervention, Symptomatic Relief, and Effective Therapy, Allergy & Immunology Report, (Selected reports from the 2004 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, 2005; 1(2): 12-19.

213. Lockey RF:
News from EAACI, (Frew elected EAACI president), Academy News, 2005; 11(5).

214. Lockey RF:

215. Lockey RF:

216. Lockey RF:

217. Pierce C, Lockey RF:
US focuses on anaphylaxis. EAACI Newsletter, 2005; 7:15.

218. Mohapatra SS, Lockey RF, Shirley S:


220. Lockey RF:

221. Zhang W, Lockey RF, Mohapatra SS:

222. Lieberman PL, Kaliner M, Lockey RF, Simons E:
223. Lockey RF:
   EAACI News – XXV EAACI Annual Conference visits Vienna. *Academy News*,
   (American Academy of Allergy, Asthma and Immunology), 2006; 12(5):16.

224. King MJ, Lockey RF:
   How best to diagnose and control asthma in the elderly. *J Respir Dis*, 2006; 27(6):
   238-247.

225. Kearney DM, Lockey RF:

226. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R,
   Price D, Bousquet J:
   ARIA update: I – Systematic review of complementary and alternative medicine for

227. Ramey JT, Lockey RF:
   Allergic and nonallergic reactions to nitroglycerin. *Allergy Asthma Proc*, 2006;

228. Ramey JT, Bailen E, Lockey RF:
   Rhinitis medicamentosa: a review. *J Investig Allergology Clin Immunol*, 2006,

   J, Bunnag C, Canonica GW, Carlsen KH, Chen YZ, Cruz AA, Custovic A, Demoly P,  
   Dubakiene R, Durham S, Fokkens W, Howarth P, Kemp J, Kowalski ML, Kvedariene V, 
   Lipworth B, Lockey RF, et al:
   Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in 
   collaboration with GA³LEN). *Allergy*, 2006; 61(9): 1086-96.

230. Lockey RF:

231. Lockey RF:
   Rhinitis medicamentosa and the stuffy nose. *J Allergy Clin Immunol*,

232. Codina R, Lockey RF:
   Indoor allergen assessments – A call for universal standards. *J Allergy Clin Immunol*,

233. Kaliner MA, Lockey RF:

234. Canonica GW, Baena-Cagnani C, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ,
   Passalacqua G, Potter P, Valovirta E:
   Recommendations for standardization of clinical trials with allergen specific
   immunotherapy for respiratory allergy – A statement of a World Allergy
   62(3): 317-324.
235. Lockey RF (contributor):
Passalacqua G, Durham SR:

236. Lockey RF:
Thomas B. Casale – the new President of the AAAAI. EAACI Newsletter 2007; 12: 19.


238. Lupoli T, Lockey RF:

239. Lockey RF, Mohapatra SS:
WAO News & Notes, December 2006 Medical Journal Review.

240. Canonica GW, Passalacqua G, Lockey RF, Pawankar R, Potter P:

241. Kaliner M, Lockey RF:

242. Varghese M, Lockey RF:

243. Lockey RF:

244. Mohapatra SS, Lockey RF:

245. Kemp SF, Lockey RF, Simons FER, on behalf of the World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis:


269. Lockey RF (Reviewer):
Uniform definition of asthma severity, control, and exacerbations: Document
presented for the World Health Organization Consultation on Severe Asthma.  
*J Allergy Clin Immunol* 2010; 126(5): 926-938.

270. Pesek R, Lockey RF:

271. Lockey RF, Hankin CS:
Health economics of allergen-specific immunotherapy in the United States.  

272. Hankin CS, Lockey RF:
Patient characteristics associated with allergen immunotherapy initiation and adherence.  

273. Rael E, Lockey RF:
Interleukin-13 signaling and its role in asthma.  
*WAO Journal* 2011; 4(3): 54-64.

274. Wang JW, Li K, Hellermann G, Lockey RF, Mohapatra S, Mohapatra SS:
Regulating the regulators: microRNA and Asthma.  

275. Alkhalil M, Lockey RF:
Pediatric obstructive sleep apnea syndrome (OSAS) for the allergist: update on the assessment and management.  

276. Fitzhugh D, Lockey RF:
History of immunotherapy: The first 100 years.  

World allergy guidelines for the assessment and management of anaphylaxis.  

278. Butt A, Rashid D, Lockey RF:

Davos Declaration: Allergy as a global problem.  *Allergy* 2012; 67: 141-143.

280. Calderon MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P:
Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.  
*Allergy* 2012; 67: 302–311.

281. Lockey RF:
282. Lötvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, Burks WA, Casale TB, Lockey RF, Papadopoulos NG, Fineman SM, Ledford DK, American Academy of Allergy Asthma & Immunology (AAAAI); American College of Allergy, Asthma & Immunology (ACAAI); European Academy of Allergy and Clinical Immunology (EAACI); World Allergy Organization (WAO):


284. Lockey RF:

285. Lockey RF (contributor):
Sumino K, Holbrook JT, Wise RA, Rogers L:


287. Bousquet J, Schunemann HJ, Samolinski B, Lockey RF, et al:
ARIA (Allergic rhinitis and its impact on asthma) – achievements in 10 years and future needs. JACI 2012; 130(5):1049-62.

288. Pawankar R, Canonica W, Holgate S, Lockey RF:


291. Ledford DK, Lockey RF:

292. Pesek RD, Lockey RF:
Management of Insect Sting Hypersensitivity: An Update.
*Allergy, Asthma & Immunology Research* 2013; 5(3): 129.

293. Lane T, Flam B, Lockey RF, Kolliputi N:
Doi: 10.3389/fphys.2013.00050

294. Fukumoto J, Lockey R, Kolliputi N:


297. Bernstein J, Fox RW, Martin VT, Lockey RF:

298. Desai P, Parthasarathy PT, Galam L, Lockey RF, Kolliputi N:

299. Mehta J, Parthasarathy PT, Lockey RF, Kolliputi N:

300. Grams D, Lockey RF, Lockey RF, Kolliputi N:
Is isoprenylcysteine carboxyl methyltransferase the key to reverse ageing?

301. Talreja N, Lockey RF:

302. Simons FER, Arduasso LRF, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, Sanchez-Borges M, Genna GE, Sheikh A, Thong BY, Worm M:
303. Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS:
WAO White Book on Allergy: Update 2013 – Executive Summary.
World Allergy Org, 2013.

304. Qazi O, Tamarapu P, Lockey RF, Kolliputi N:

305. Wang JW, Lockey RF:
Lipopolysaccharide-responsive beige-like anchor (LRBA), a novel regulator of human immune disorders

International Consensus on (ICON) Anaphylaxis.

308. Cox LS, Hankin C, Lockey RF:
Allergy immunotherapy adherence and delivery route: location does not matter.

309. Pesek RD, Lockey RF:
Treatment of Hymenoptera venom allergy: an update.

310. Kolliputi NK, Lockey RF:
Lipoxins: A new treatment for asthma.
Allergy, Asthma & Immunology Research, accepted for publication.

311. Aljubran S, Whelan G, Glaum M, Lockey RF:
Osteoporosis in the at-risk asthmatic. Allergy, accepted for publication.

312. Lockey RF:
Adolescents and anaphylaxis. Primary Care Respiratory Journal (PCRJ), submitted.

313. Hankin C, Lockey RF:
Under-detection of allergic rhinitis.
JACI: In Practice, submitted.